Norbert Marschner

20PUBLICATIONS
11CO-AUTHORS
Predictive and prognostic markersMolecular targetsEpidemiological methodsHaematological tumoursTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Mar 18, 2026
Prediction of dose reductions and impact of reduced starting doses of CDK4/6i on effectiveness in HR-positive/HER2-negative metastatic breast cancer: Real-world data from the OPAL registry.

Patrick Marschner, Kai Ringwald, Marc Thill

|Dec 30, 2025
First-Line Treatment with Tivozanib for Metastatic Renal Cell Carcinoma in Real-World Settings Across Germany: Results of the Prospective, Non-Interventional, Post-Approval Study T-Rex.

Viktor Grünwald, Karen Rußwurm, Ralf Eckert

|Sep 09, 2025
Prospective validation of the modified metastatic colorectal cancer score (mCCS) in >600 patients with RAS-wild-type metastatic colorectal cancer treated with first-line panitumumab plus FOLFIRI/FOLFOX: Final results of the non-interventional study VALIDATE.

Karin Potthoff, Jens Uhlig, Lutz Jacobasch

|Jul 03, 2024
Head-to-head comparison of treatment sequences in advanced pancreatic cancer-Real-world data from the prospective German TPK clinical cohort study.

Norbert Marschner, Nina Haug, Susanna Hegewisch-Becker

|Jan 19, 2024
Quantifying bias due to missing data in quality of life surveys of advanced-stage cancer patients.

Nina Haug, Martina Jänicke, Benjamin Kasenda

|Sep 02, 2022
FOLFIRINOX or gemcitabine/nab-paclitaxel in advanced pancreatic adenocarcinoma: A novel validated prognostic score to facilitate treatment decision-making in real-world.

Norbert Marschner, Susanna Hegewisch-Becker, Marcel Reiser

Pageof 4

Frequent Collaborators

2 joint publications

Michael Staehler

2 joint publications

Nina Haug

1 joint publications

Benjamin Kasenda

1 joint publications

Melanie Frank